Tofacitinib: A Novel Addition to Your Toolkit

Bhargav Patel, Mercer University College of Pharmacy

Ulcerative colitis is a chronic inflammatory disease of the large intestine characterized by symptoms that include abdominal pain and bloody diarrhea. Patients may present with this condition between 15-30 years of age with standard treatment depending on the extent of involvement, disease severity, and other factors. [1] Medications such as corticosteroids, tumor necrosis factor (TNF) antagonists, and aminosalicylates are proposed to assist with remission and maintenance medications may follow to prevent with a relapse. [2] Tofacitinib is an oral, small-molecule Janus kinase (JAK) inhibitor developed to treat rheumatoid arthritis and is also being investigated for the treatment of ulcerative colitis. Preferential inhibition of JAK1/JAK3 may cause interference in the JAK-STAT signaling pathway and prevent signaling to multiple immunological mediators such as Interleukin (IL)-2, IL-4, and interferon–γ. [3]

Continue reading